Silence Seeks Share Of Alnylam RNAi Success In Legal Action
Executive Summary
The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.
You may also be interested in...
Alnylam And Silence Settle Over RNAi Patents
Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.
Win-Win For Alnylam And Dicerna With RNAi Trade Secrets Settlement
Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.
Novartis Takes Huntington's Path With SMA Therapy Branaplam
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Need a specific report? 1000+ reports available
Buy Reports